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Abstract
Aim: Colorectal carcinomas (CRCs) progress through heterogeneous pathways. The aim 
of this study was to analyse whether or not the cytogenetic evolution of CRC is linked to 
tumour site, level of chromosomal imbalance and metastasis.
Method: A set of therapy- naïve pT3 CRCs comprising 26 proximal and 49 distal pT3 CRCs 
was studied by combining immunohistochemistry of mismatch repair (MMR) proteins, 
microsatellite analyses and molecular karyotyping as well as clinical parameters.
Results: A MMR deficient/microsatellite- unstable (dMMR/MSI- H) status was associated 
with location of the primary tumour proximal to the splenic flexure, and dMMR/MSI- H 
tumours presented with significantly lower levels of chromosomal imbalances compared 
with MMR proficient/microsatellite- stable (pMMR/MSS) tumours. Oncogenetic tree 
modelling suggested two evolutionary clusters characterized by dMMR/MSI- H and chro-
mosomal instability (CIN), respectively, for both proximal and distal CRCs. In CIN cases, 
+13q, −18q and +20q were predicted as preferentially early events, and −1p, −4 - and −5q 
as late events. Separate oncogenetic tree models of proximal and distal cases indicated 
similar early events independent of tumour site. However, in cases with high CIN defined 
by more than 10 copy number aberrations, loss of 17p occurred earlier in cytogenetic 
evolution than in cases showing low to moderate CIN. Differences in the oncogenetic 
trees were observed for CRCs with lymph node and distant metastasis. Loss of 8p was 
modelled as an early event in node- positive CRC, while +7p and +8q comprised early 
events in CRC with distant metastasis.
Conclusion: CRCs characterized by CIN follow multiple, interconnected genetic path-
ways in line with the basic ‘Vogelgram’ concept proposed for the progression of CRC that 
places the accumulation of genetic changes at centre of tumour evolution. However, the 
timing of specific genetic events may favour metastatic potential.
K E Y W O R D S
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INTRODUC TION
Colorectal cancer (CRC) is one of the most common types of can-
cer in both women and men [1,2]. This malignancy represents a 
heterogeneous group of tumours with regard to clinical, morpho-
logical and pathogenetic characteristics [3– 5]. CRC has been sug-
gested to comprise a proximal, right- sided subtype that arises in the 
midgut- derived part of the large bowel and a distal, left- sided sub-
type arising in the hindgut- derived bowel [3], although transitions of 
the phenotype may be gradual [6]. Compared with left- sided CRCs, 
right- sided CRCs show a moderate female predominance and the 
mean age at diagnosis is higher [7]. Mucinous or undifferentiated 
phenotypes are preferentially observed in right- sided CRCs, and the 
disease stage appears to be more advanced [7]. A site preference has 
also been observed for CRCs related to tumour predisposition syn-
dromes. In patients with Lynch syndrome, CRCs typically occur in 
the right- sided colon [8]. In the distal colon and rectum, familial ad-
enomatous polyposis coli syndrome (FAP)- associated CRC appears 
to be more common, although FAP patients may also develop CRC in 
the right- sided colon [8].
It is established that CRC develops through several pathways 
resulting in different cytogenetic and molecular characteristics of 
the tumour [9]. The largest subset of CRCs evolves through chro-
mosomal instability (CIN), which results in common chromosomal 
aberrations including losses at 8p, 17p and 18q as well as gains at 7p, 
7q, 8q, 13q and 20q, and more variably losses at 1p, 4p, 4q, 5q, 14q, 
15q and 18p as well as gains at 1q and 20p [10– 17]. In contrast, CRCs 
with a high degree of microsatellite instability (MSI- H) [18– 20] often 
present with a stable, near- diploid karyotype, although some MSI- H 
tumours show chromosomal imbalances as well [21– 25]. MSI- H is 
characterized by disruption of the DNA mismatch repair (MMR) sys-
tem that maintains DNA sequence fidelity [26]. In Lynch syndrome, 
germline pathogenic variants in any of the MMR genes MLH1, MSH2, 
MSH6 and PMS2, or in EPCAM (deletions in the latter non- MMR gene 
result in silencing of the adjacent MMR gene MSH2 [27]), predispose 
to the development of CRC with an MSI- H phenotype [28– 31]. In 
sporadic CRCs, MMR deficiency is caused by expression loss of 
MMR genes, which commonly originates from epigenetic silencing 
of the MLH1 gene by promoter methylation [32– 34]. MLH1 promoter 
methylation correlates with a high CpG island methylator phenotype 
(CIMP- H) [35]; however, methylation of the MLH1 promoter also oc-
curs in CIMP- negative or CIMP- low tumours [36].
In a collaborative effort, the CRC Subtyping Consortium sug-
gested a stratification of CRCs into the following four consensus 
molecular subtypes (CMS) [9]. (1) Tumours belonging to CMS1 – the 
MSI immune subtype – share MSI- H, CIMP- H and a hypermutation 
phenotype; these tumours commonly harbour BRAF mutations and 
are characterized by activation of immune cells [9]. (2) CIN is pre-
dominant in CMS2 tumours (canonical subtype), which reveal acti-
vation of MYC and the WNT pathway [9]. (3) In CMS3, metabolic 
deregulation dominates the phenotype; both CIN and CIMP status 
are low, and tumours typically harbour KRAS mutations. (4) The mes-
enchymal subtype, CMS4, shares CIN with CMS2, but demonstrates 
activation of the transforming growth factor beta pathway [9]. 
Mixed subtypes may be observed in a minority of CRCs [9].
Several models have been put forward to describe the temporal 
order of genetic alterations acquired during the development of CRC. 
In 1990, Fearon and Vogelstein linked recurrent genetic alterations 
to the adenoma- to- carcinoma sequence [37]. In their progression 
model, commonly referred to as the ‘Vogelgram’, colorectal tumouri-
genesis is typically initiated by the loss of APC favouring hyperpro-
liferation of the intestinal epithelium, followed by somatic mutations 
in KRAS, loss of 18q as well as loss of TP53, ultimately resulting in 
invasive cancer [37]. The Vogelgram model, however, should be in-
terpreted as preferred, but not the exclusive order of genetic events 
(i.e. the genetic alterations may occur in any order) [37]. Later, the 
MSI- H pathway was integrated into the progression model of CRC 
as a distinct pathway separated from the Vogelgram pathway [38]. 
The basic concept of the evolutionary model was corroborated in a 
recent study of the International Cancer Genome Consortium/The 
Cancer Genome Atlas (ICGC/TCGA) Pan- Cancer Analysis of Whole 
Genomes (PCAWG) Consortium, which devised driver mutations in 
APC, KRAS, PIK3CA, TP53 and FBXW7 as well as the chromosomal 
imbalances +8q, −17p and −18q as preferentially early events [39]. 
The aim of the present study was to address whether or not the cy-
togenetic evolution of CRC is specific for certain tumour character-
istics. To this end, oncogenetic trees were reconstructed for CRCs 
using maximum likelihood estimation [40] and maximum- weight 
branching approaches [41,42] to model the evolution of common 
chromosomal imbalances and the MMR/microsatellite (MS) status in 
proximal and distal CRCs.
METHOD
Study cohort
This study was approved by the local ethics committee. Ethics ap-
proval was obtained for all cases included in the study. To minimize 
differences related to tumour stage, only locally advanced (pT3) 
CRCs were included in the current series. The cohort comprised 75 
primary CRCs, including 26 proximal CRCs (located in the caecum, 
What does this paper add to the literature?
This paper addresses the tumour evolution of colorectal 
cancer (CRC) and demonstrates that in addition to the mis-
match repair- deficient/microsatellite- unstable pathway, 
CRCs characterized by chromosomal instability follow dif-
ferent, interconnected genetic pathways. These results 
provide evidence for the ‘Vogelgram’ concept, which in-
dicates that accumulation of genetic alterations dictates 
tumour evolution, but also suggest a role for the timing of 
the genetic events.
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ascending colon, hepatic flexure or colon transversum) and 49 distal 
CRCs (located in the rectum, i.e. aboral tumour margin up to 16 cm 
from the anal verge). Pathological staging was performed accord-
ing to the recommendations of the Union for International Cancer 
Contro (UICC) published in 2016 [43]. Primary resection of all CRCs 
was performed. Patients diagnosed with clinical UICC Stage IV CRC 
underwent surgery of the primary tumour as well as of resectable 
liver metastasis with potentially curative intent as a single case deci-
sion after discussion in a multiprofessional interdisciplinary tumour 
board. Patients with locally advanced rectal cancers (clinically staged 
as UICC Stages II and III) were treated within or according to the 
control arm of the CAO/ARO/AIO- 94 phase III trial of the German 
Rectal Cancer Study Group with primary surgery, typically followed 
by postsurgery fluorouracil (5- FU)- based chemoradiotherapy or 
5- FU monotherapy [44,45]. Thus, only naïve tumour material was 
analysed in this study, i.e. the tumour material was obtained prior to 
any postoperative irradiation and/or chemotherapy. Vital status was 
available for all patients; complete information on patient follow- up 
(mean 39 months, median 40 months, maximum 103 months) was 
available for 70 patients. Overall survival (OS) was the time between 
surgical treatment and the date of death, irrespective of cause.
Immunohistochemical MMR analysis
Immunohistochemical studies on formalin- fixed, paraffin- embedded 
tumour tissue were performed for MLH1 (clone G168- 15; BD 
Biosciences, Franklin Lakes, NJ, USA; dilution 1:50; microwave pre-
treatment), MSH2 (clone FE11, Zytomed Systems GmbH, Berlin, 
Germany; dilution 1:50; microwave pretreatment), MSH6 (clone 44, 
BD Biosciences; dilution 1:50; microwave pretreatment) and PMS2 
(clone A16- 4, BD Biosciences; dilution 1:50; microwave pretreat-
ment) using the DAKO ChemMate™ Detection Kit (Dako, Glostrup, 
Denmark) for visualization. Noncancerous intestinal crypt cells, 
lymph follicles and stromal cells served as internal controls for the 
staining reactions. Negative protein expression of the respective 
MMR protein was defined as complete loss of nuclear staining within 
the tumour. Immunohistochemical slides were evaluated without 
knowledge of the MSI results. Tumours with aberrant staining loss 
of a pair of MMR proteins or individual loss of PMS2 or MSH6 were 
classified as MMR deficient (dMMR), while tumours with no loss of 
staining were classified as MMR proficient (pMMR).
MSI analysis
For selected cases, analysis of microsatellites was performed on 
DNA extracted from formalin- fixed and paraffin- embedded tissue 
blocks. We used the Promega MSI Multiplex System Version 1.2 
(Promega, Madison, WI, USA) according to the manufacturer's in-
structions, which offers five nearly monomorphic mononucleotide 
repeat markers (BAT- 25, BAT- 26, NR- 21, NR- 24 and MONO- 27) for 
MSI determination and two polymorphic pentanucleotide markers 
(Penta C and Penta D) for sample identification. Products were 
separated by capillary electrophoresis using an ABI 3100 Genetic 
Analyser (Applied Biosystems, Foster City, CA, USA). Tumours with 
MSI at two or more mononucleotide loci were stratified as MSI- H, 
while tumours with MSI at a single mononucleotide locus were MSI- 
low (MSI- L) and tumours with no MSI at any of the loci tested were 
MS- stable (MSS) [46].
Analysis of chromosomal imbalances
Tumour DNA was isolated from formalin- fixed and dewaxed tumour 
tissue sections and analysed by comparative genomic hybridiza-
tion (CGH) as detailed previously [47]. The Quips Karyotyping/CGH 
software suite (Vysis, Downers Grove, IL, USA) was used to obtain 
green- to- red fluorescence ratios for each metaphase chromosome. 
Gains, high- level amplifications and losses were defined as chromo-
somal regions where the average green- to- red fluorescence ratio 
was >1.2, >2 and <0.8, respectively. In exceptional cases, where the 
aforementioned thresholds were not met, deviations from normal 
were classified as gains or losses when the 95% confidence interval 
varied beyond the ratio of 1.0. The following chromosomal regions 
that are known for false results were not included in the analysis: 
1p32pter, 13p, 14p, 15p, 21p, 22p, telomeres and constitutive het-
erochromatic regions at 1q, 9q, 16q and Yq [48]. Aneuploidy scores 
were used to quantify chromosomal arm aneuploidy and calculated 
as the total number of chromosomal arms with an apparent whole 
arm gain or loss [49]. Short arms of acrocentric chromosomes (i.e. 
chromosomes 13, 14, 15, 21 and 22) were not included in the ane-
uploidy score.
Statistical analysis
Statistical analyses were performed using the software platform 
R [50]. Fisher’s exact test for contingency tables was used to ana-
lyse clinico- pathological parameters. For the statistical test of net 
changes and aneuploidy score versus localization, the two- sided 
Wilcoxon rank sum test with continuity correction was selected as 
the Shapiro– Wilk normality test indicated nonnormally distributed 
data. The Mantel– Haenszel log- rank test for censored data was 
selected for the correlation of clinico- pathological characteristics 
and individual imbalances identified in the tumours. Survival was 
estimated using Kaplan– Meier curves. The Benjamini– Hochberg 
method was used to correct for multiple testing. A p- value <0.05 
was considered statistically significant.
Oncogenetic tree models
An oncogenetic tree model using maximum likelihood estimation 
[40] was reconstructed using the entire study cohort, i.e. independ-
ent of the tumour location. To this end, the R package ‘oncomodel’ 
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(https://cran.r- proje ct.org/web/packa ges/oncom odel/index.html) 
was selected. The MS status as well as the most common chromo-
somal imbalances observed in the cohort were included in the mod-
elling. Additionally, maximum- weight branching oncogenetic tree 
models [41,42] were separately computed for proximal and distal 
CRCs using the R package ‘OncoTree’ (https://cran.r- proje ct.org/
web/packa ges/Oncot ree/index.html), as were oncogenetic trees for 
CRCs stratified according to the number of chromosomal imbalances 
(with categories ≤10 and >10 being aberrations), the node status 
(with categories pN0, pN1a/b, pN2a/b) and presence or absence of 
distant metastasis (with categories no metastasis, synchronous me-
tastasis, metachronous metastasis).
RESULTS
Clinico- pathological characteristics of the patient 
cohort
The study included 75 patients with primary CRC (Table 1). The age 
of the patients at the time of diagnosis ranged from 29 to 87 years 
(mean 64.4 years) in the proximal CRC group and from 44 to 89 years 
(mean 68.6 years) in the distal CRC group. There were 31 women 
and 44 men in our cohort. Twenty six patients (35%) had a CRC prox-
imal to the splenic flexure and 49 (65%) a distal CRC. Among the 26 
patients with proximal pT3 CRCs, 10 (38%) were in clinical Stage IIA 
(pN0), 7 (27%) in clinical Stage IIIB (pN1 or pN2a), 1 (4%) in clinical 
Stage IIIC (pN2b) and 8 (31%) in clinical Stage IVA (M1a). Among the 
49 patients with distal pT3 CRC, 23 (47%) were in clinical Stage IIA, 
10 (20%) in clinical Stage IIIB, 12 (24%) in clinical Stage IIIC, 3 (6%) in 
clinical Stage IVA and 1 (2%) in clinical Stage IVB (M1b).
There were significant differences in the rate of synchronous 
versus metachronous metastatic disease between the proximal and 
distal CRCs (p = 0.02, Fisher's exact test). In particular, proximal 
CRCs were more likely to show synchronous metastasis [8/26 (31%) 
vs. 4/49 (8%) of the distal CRCs], while metachronous metastasis 
was predominantly observed in distal CRCs stratified as cM0 at ini-
tial cancer staging [1/17 (6%) of the proximal CRCs vs. 9/40 (23%) 
of the distal CRCs]. A positive node status (p = 2.9 × 10−6) and the 
disease stage (p = 1.7 × 10−4, log rank/Mantel– Haenzel test) were 
significant predictors of OS (Figure 1). However, we did not observe 
a significant difference in the OS between the proximal and the dis-
tal CRCs (p > 0.05). Likewise, no significant differences in the OS 
were noted between the proximal and the distal tumour site among 
patients with tumours of the same clinical stage (p > 0.05 for clinical 
Stage II, III and IV).
MMR protein expression and microsatellite analysis
Immunohistochemically, 65 of the tumours (87%) showed nuclear 
expression of the MMR proteins MLH1, MSH2, MSH6 and PMS2 
(Table 1). In the remaining 10 tumours, there was complete absence 
of nuclear staining for at least one MMR protein. Specifically, loss 
of expression was observed for PMS2 in 8 (11%) cases, for MLH1 
in 6 (8%) cases, for MSH6 in 2 (3%) cases and for MSH2 in 1 (1%) 
case (Table 1). Isolated loss of expression of PMS2 and MSH6 was 
found in two tumours and one tumour, respectively. There was con-
current negative expression of MLH1/PMS2 in six cases, represent-
ing 100% of MLH1- negative cases and 75% of PMS2- negative cases. 
Concurrent negative expression of MSH2/MSH6 was observed in 
one tumour.
For ten selected cases, the MS status was determined by com-
plementary MSI analysis. In all but one case, the MS status indicated 
by the immunohistochemical analysis of the MMR proteins was con-
firmed by the MSI analysis. However, one tumour showing loss of 
PMS2 expression and an above average level of DNA copy number 
aberrations (case 16 with 14 chromosomal imbalances) was reclassi-
fied as MS- stable based on the result of the MSI analysis. Thus, with 
complementary MSI analysis, 66 tumours were classified as pMMR/
MSS and 9 tumours as dMMR/MSI- H, representing 27% of the prox-
imal CRCs and only 4% of the distal CRCs (7/26 vs. 2/49; p = 0.02; 
Fisher's exact test). Overall, there were no significant differences 
in the OS when the dMMR/MSI- H and pMMR/MSS tumours were 
compared (p > 0.05; log rank/Mantel– Haenzel test).
Chromosomal imbalances
DNA copy number aberrations were detected in 66 of the 75 CRC 
cases (88%) (Figure 2; details are provided in Table 1). The two most 
common autosomal imbalances were +20q (61%) and −18q (60%), 
followed by, in decreasing frequency, +13q (45%), +8q (35%), −8p 
(33%), −4q (31%), −18p (27%), +20p (27%), −4p (23%), −14q (23%), 
−1p, (20%), +7p (20%), −5q (19%), −17p (19%), +12p (16%) and −15q 
(16%) (Figure 2).
Proximal pT3 CRCs revealed a significantly lower number of 
chromosomal imbalances than distal pT3 CRCs (mean 5.3 vs. 8.8; 
p = 0.02; Wilcoxon test; Table 2), including fewer gains and amplifi-
cations (mean 2.8 vs. 4.1; p = 0.047; Wilcoxon test) and fewer losses 
(mean 2.4 vs. 4.6; p = 0.03; Wilcoxon test). There was a trend to-
ward higher rates of karyotypes devoid of apparent chromosomal 
imbalances in proximal CRCs compared with distal CRCs (6/26 vs. 
3/49; p = 0.08; Fisher's exact test). The significantly lower number of 
chromosomal imbalances observed in proximal CRCs appeared to be 
correlated with the higher frequency of proximal CRCs showing the 
dMMR/MSI- H phenotype. When the proximal and distal CRCs were 
compared according to the MMR/MS status, no significant differ-
ences in the number of chromosomal imbalances were seen for the 
proximal and distal CRCs (p > 0.05 for the pMMR/MSS and dMMR/
MSI- H cases; Wilcoxon test; Table 2).
The majority of the CRCs (i.e. 62 tumours, 83%) analysed in this 
study showed chromosome arm aneuploidy defined as at least one 
imbalance that apparently encompassed the whole chromosome arm. 
Aneuploidy scores were separately determined for both the proximal 
and distal CRCs (Table 2). As for the total number of chromosomal 
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imbalances, the mean aneuploidy score was significantly lower in 
proximal CRCs than in distal CRCs (aneuploidy score of 3.8 vs. 6.6; 
p = 0.02; Wilcoxon test; Table 2). However, when the MMR/MS sta-
tus was taken into account in addition to the tumour site, no signif-
icant differences were obtained (p > 0.05 for the pMMR/MSS and 
dMMR/MSI- H tumours; Wilcoxon test; Table 2), in line with the re-
sults obtained for the total number of chromosomal imbalances.
Subsequently, we sought to identify particular chromosomal 
changes that might distinguish tumours by anatomical site. However, 
there was no universal chromosomal marker that distinguished be-
tween proximal and distal CRCs. If any, there were differences in the 

























































































































































































































































































































































































































































































F I G U R E  1  Overall survival of colorectal cancer patients 
stratified according to the node status and UICC stage 















p = 2.9 × 10-6
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F I G U R E  2  Pattern of copy number 
aberrations observed in 26 proximal 
colorectal cancers (CRCs; background 
in grey, bottom) and 49 distal CRCs 
(background in light grey, top). Losses 































































(n = 26) Distal CRC (n = 49)
Site- dependent 
differences
Mean (range) Mean (range) p- value
No. of imbalances (all) 5.3 (0– 24) 8.8 (0– 27) 0.02
No. of imbalances (pMMR/
MSS)
6.8 (0– 24) 9.1 (0– 27) ns
No. of imbalances (dMMR/
MSI- H)
1.0 (0– 4) 0.0 (0) ns
Aneuploidy score (all) 3.8 (0– 17) 6.6 (0– 19) 0.02
Aneuploidy score (pMMR/
MSS)
4.9 (0– 17) 6.9 (0– 19) ns
Aneuploidy score (dMMR/
MSI- H)
1.0 (0– 4) 0.0 (0) ns
Note: The total number of chromosomal imbalances (i.e. focal and arm- level copy number 
aberrations) and the aneuploidy score (i.e. number of apparent arm- level imbalances) are listed. 
Significant p- values are shown in bold.
Abbreviation: dMMR, deficient mismatch repair; MSI- H, microsatellite- unstable, high degree; MSS, 
microsatellite- stable; ns, not significant; pMMR, proficient mismatch repair.
TA B L E  2  Site- dependent differences 
in copy number aberrations between 26 
proximal pT3 colorectal cancers (CRCs) 
and 49 distal pT3 CRCs
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degree of chromosomal imbalances in proximal CRCs, statistical analysis 
revealed −18q (35% vs. 73%.; p = 0.007; Fisher's exact test), +20q (38% 
vs. 73%; p = 0.02; Fisher's exact test) and −15q (0% vs. 24%; p = 0.02; 
Fisher's exact test) to be less common in proximal CRCs than in distal 
CRCs. The overall pattern of chromosomal imbalances, however, did not 
differ substantially between proximal and distal CRCs (Figure 2).
Compared with pMMR/MSS CRCs, dMMR/MSI- H tumours ap-
peared to have significantly lower levels of chromosomal imbalances 
(mean 8.5 for pMMR/MSS tumours vs. 0.8 for dMMR/MSI- H CRCs; 
p = 0.0003; Wilcoxon test), an association which held true for both 
proximal and distal CRCs. There were seven dMMR/MSI- H tumours 
(five proximal and two distal CRCs) with concurrent karyotype lacking 
apparent chromosomal imbalances, representing 71% (5/7) of proxi-
mal dMMR/MSI- H tumours and all (2/2) of the distal dMMR/MSI- H 
tumours. Specifically, dMMR/MSI- H CRCs presented with lower fre-
quencies of −18q (p = 0.0006; Fisher's exact test), +20q (p = 0.0006), 
+13q (p = 0.01) and −8p (p = 0.047) than pMMR/MSS tumours. In 
comparison, only two pMMR/MSS tumours (one proximal and one dis-
tal CRC) had a karyotype without apparent copy number aberrations.
Oncogenetic tree modelling
Finally, we modelled the genetic evolution of the CRCs in our series. To 
this end, we took advantage of oncogenetic tree modelling. Maximum 
likelihood estimation was first performed for the entire cohort and 
considered the MMR/MS status and the 12 most common copy num-
ber aberrations observed in our cohort. The oncogenetic tree model 
suggested the presence of two main clusters (Figure 3). Cluster I com-
prised CRCs with dMMR/MSI- H, while cluster II was characterized by 
the presence of CIN. In the latter, four subclusters were obtained: a 
+8q subcluster with correlation of +7p, −8p and +8q; a +13q cluster 
comprising −1p, −4p, −4q, +13q, −14q and +20p; an −18q subcluster 
with −18p and −18q; and a +20q subcluster (Figure 3).
To model the evolution of the CRCs dependent on the tumour site, 
maximum- weight branching oncogenetic tree models were recon-
structed separately for the proximal and distal CRCs in order to pre-
dict cancer evolution (Figure 4). The derived models support multiple 
possible orders of accumulation of chromosomal imbalances. As for 
the maximum likelihood- based model (Figure 3), the maximum- weight 
branching oncogenetic tree models predicted an dMMR/MSI- H clus-
ter for both the proximal and distal CRCs (Figure 4). Moreover, for the 
proximal CRCs, +13q and +20q were placed close to the root, suggest-
ing these copy number aberrations to represent early events in tumour 
evolution (Figure 4A). The +13q subcluster was suggested to prog-
ress via different paths. For the distal CRCs, paths via +8q, −18q and 
+20q were predicted, and tumours in the −18q subcluster appeared 
to acquire multiple further chromosomal aberrations (Figure 4B). 
Remarkably, gain of 8q was indicated as a rather late event in proximal 
CRCs, while it was modelled as an early event in distal CRCs.
Furthermore, when divided according to the number of chromo-
somal imbalances (≤ 10 vs. >10 aberrations), overall similar trees were 
built for the two groups, indicating that cases with low to moderate 
CIN and high CIN exhibit similar changes (Figure 5). In particular, +13q, 
−18q and +20q were predicted as preferentially early events, while 
aberration −1p, amongst others, was predicted as a late event in CRC 
evolution. A differential positioning, however, was observed for −17p, 
which was predicted to represent a late event in the low to moderate 
CIN group but an early event in the group showing high CIN (Figure 5).
Finally, we modelled the cytogenetic evolution dependent on 
the node status and distant metastatic disease using maximum- 
weight branching oncogenetic tree models. Again, these models 
shared +13q, −18q and +20q as preferentially early events irrespec-
tive of the node status (Figure 6) or presence of distant metastasis 
(Figure 7), respectively. However, −8p was modelled as an early event 
in node- positive CRCs (Figure 6B,C) but as a late event in CRCs with 
pN0 status (Figure 6A). Moreover, +7p and +8q occurred early in 
the cytogenetic evolution of CRCs presenting with synchronous and 
metachronous distant metastasis (Figure 7B,C). In contrast, these 
chromosomal imbalances were late events in CRCs that showed no 
clinical sign of distant metastasis (Figure 7A). Cytogenetic tree mod-
elling thus identified distinct patterns of chromosomal imbalances 
dependent on tumour characteristics.
DISCUSSION
Clinico- pathological differences of right- sided and left- sided CRCs 
suggest different aetiological backgrounds and the existence of 
F I G U R E  3  Oncogenetic tree model for the genetic evolution 
of proximal and distal colorectal cancers reconstructed using 
maximum- likelihood estimation. Events predicted to occur early 
are placed in proximity to the root (grey box). Cluster I marked 
by dMMR/MSI- H (deficient mismatch repair/high degree of 
microsatellite instability) and cluster II marked by chromosomal 
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multiple categories of CRCs [3– 5,7,8,]. Herein, oncogenetic tree 
modelling of the MS status combined with copy number aberrations 
indicated that it is the type of genomic instability, i.e. CIN [10,11] 
or dMMR/MSI- H [19,20] that represents a central criterion in the 
stratification of CRCs, independent of the tumour site. Accordingly, 
the oncogenetic tree models presented herein predicted two similar 
main clusters for both proximal and distal CRCs, one cluster charac-
terized by dMMR/MSI- H and the other cluster by multiple chromo-
somal imbalances.
In the present series, MMR immunohistochemistry and MSI anal-
ysis identified nine dMMR/MSI- H tumours, representing 27% of the 
proximal CRCs but only 4% of the distal CRCs. These dMMR/MSI- H 
tumours were found to have either no or a limited number of chro-
mosomal imbalances, which supports previous observations that 
dMMR/MSI- H tumours present with lower degrees of chromosomal 
imbalances than pMMR/MSS tumours [21– 24]. The significantly 
lower number of chromosomal imbalances and a trend toward higher 
rates of karyotypes without apparent copy number aberrations ob-
served in the proximal CRC group could be attributed to the higher 
frequency of dMMR/MSI- H tumours at this site. Accordingly, we did 
not observe significant differences in the number of chromosomal 
imbalances when only pMMR/MSS tumours were compared.
Chromosomal imbalances identified in dMMR/MSI- H tumours in 
our series were gains of chromosomes 7, 8 and 12, which apparently 
involved whole chromosomes, in addition to a loss of 21q (note that 
21p cannot be addressed with the method used). Gains of chromo-
somes 7 [23,24] and 12 [24] were previously observed in dMMR/
MSI- H CRCs, and also whole- chromosomal gains of chromosome 8 
were consistently reported for dMMR/MSI- H CRCs [23]. In contrast, 
it is isochromosome 8q (resulting in −8p and +8q) [51] that appears to 
be enriched in pMMR/MSS CRCs [52]. We did not observe gains of 
chromosome 13q, one of the predominant chromosomal aberrations 
F I G U R E  4  Maximum- weight branching 
oncogenetic tree models for proximal 
(A) and distal colorectal cancer (CRC) (B). 
Early events are located close to the root 
(grey boxes) of the tree. dMMR/MSI- H, 
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found in pMMR/MSS CRCs [14], in the dMMR/MSI- H CRCs in our 
series. The frequency of dMMR/MSI- H CRC presenting with gains 
of 13q appears to differ markedly in previous reports amounting to 
5%– 60% [22– 25]. Further studies with larger cohorts are required 
to address the occurrence of +13q in dMMR/MSI- H tumours. The 
low frequency of −18q appears to represent a consistent feature of 
dMMR/MSI- H CRC [22– 25], in line with our results.
In the CIN subset of tumours, there was little qualitative varia-
tion in the pattern of chromosomal imbalances between proximal 
and distal CRCs. Our data suggested that tumours assigned to the 
CIN cluster can evolve through multiple, interconnected pathways: 
a +8q subcluster, a +13q subcluster, a +20q subcluster and a −18q 
subcluster. The subclusters, however, do not represent mutually 
exclusive pathways but rather are correlated and emerge from the 
root of the maximum likelihood- based oncogenetic tree as a com-
mon trunk.
Gains at 13q and 20q as well as losses at 18q observed in the 
CIN cluster are among the most common chromosomal imbalances 
identified in CRCs [14,53– 60], and −18q and +20q – in addition to 
−8p and +8q – have been suggested to represent early events in 
previous tree analyses of CRCs [61]. In another study, +8q and −18 
with losses at 17p were modelled to represent preferentially early 
events, and gains at 2q, 7p, 13q and 20q as well as losses at 4q, 8p 
and 14q to occur later during the evolution of the CRC [39]. While 
the general concept described in the latter study agrees with our 
series, our oncogenetic tree models favour a model in which gains at 
F I G U R E  5  Maximum- weight branching 
oncogenetic tree models for colorectal 
cancer (CRC) with a low to moderate 
(A) and high degree (B) of chromosomal 
instability. Events close to the root (grey 
boxes) of the tree represent early events. 
A total of 10 copy number aberrations 
(CNA) was used as the cutoff. dMMR/
MSI- H, deficient mismatch repair/high 
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F I G U R E  6  Maximum- weight branching 
oncogenetic tree models for colorectal 
cancers with negative node status (pN0) 
(A), pN1a/b (B) and pN2a/b (C). The root 
(grey boxes) of the tree is indicated. 
dMMR/MSI- H, deficient mismatch repair/
high degree of microsatellite instability
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F I G U R E  7  Maximum- weight branching 
oncogenetic tree models for colorectal 
cancer without distant metastasis (A), 
with synchronous metastasis (B) and with 
metachronous metastasis (C), respectively. 
The grey box marks the root of the tree. 
dMMR/MSI- H, deficient mismatch repair/
high degree of microsatellite instability
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20q and 13q represent early events in the development of CRC. In 
contrast to the aforementioned pattern of copy number aberrations 
in CRC, the rate of losses at 17p, which amongst others harbours the 
central tumour suppressor gene TP53, appears to vary considerably 
in the published cohorts [14,54,56– 58,62,63]. The −17p rate in our 
cohort is in a similar range in a subset of these studies [56,57,63].
When the CRCs were stratified according to the number of chro-
mosomal aberrations into a group with low to moderate CIN (≤10 
aberrations) and a group with a high degree of CIN (>10 aberrations), 
a differential positioning of −17p in the oncogenetic tree was ob-
served. In CRCs with low to moderate CIN, −17p was predicted as 
a late event, while it was predicted as an early event in CRCs with 
high CIN. Collectively, these results suggest a differential role of 
−17p in the evolution of CRCs with low to moderate CIN and high 
CIN, and add to a model in which multiple pathways are active in 
these groups. Along these lines, −17p has been previously linked to 
increased CIN [64].
The oncogenetic tree reconstruction following a subdivision ac-
cording to the node status and distant metastatic disease suggested 
distinct differences in the cytogenetic evolution of CRCs. In particu-
lar, loss of the short arm of chromosome 8 was predicted as an early 
event in tumours with positive node status. However, we did not 
observe major differences in the positioning of +8q in oncogenetic 
trees, an aberration previously suggested to be enriched in CRC with 
lymph node metastasis [16]. Thus, the point in time when +8q is ac-
quired might be less relevant for the potential of the tumour cells to 
form lymph node metastasis. In CRCs with synchronous and meta-
chronous metastatic disease, gains of chromosome 8q and, in partic-
ular, of 7p, which was previously linked to liver metastasis [65], were 
indicated as early events in cytogenetic evolution. Of note, recent 
studies using paired primary CRCs and their distant metastasis are 
in line with a model in which tumour spreading to distant sites takes 
place early in the disease in at least a subset of patients [66,67].
Furthermore, our oncogenetic tree modelling attributed −1p, −4 
and −5q, amongst others, as late events in tumour evolution. Hepatic 
metastasis was previously shown to be enriched in losses at 1p [17], 
and loss of chromosome 4 has been linked to advanced stages and 
metastatic events in patients with CRCs [65]. Loss of 5q was shown 
to represent an aberration acquired in brain and pulmonary metasta-
sis of CRCs, while – 5q was only rarely observed in the corresponding 
primary tumours [12,13], which independently provides evidence 
for −5q as a late event. Thus, our oncogenetic tree models captured 
differential evolutionary events in CRCs.
Remarkably, some of the copy number aberrations observed 
in the CRC series reported herein have also been demonstrated in 
subsets of colorectal adenomas [53,62,68– 70], indicating that these 
chromosomal imbalances are acquired early in disease development. 
In a recent study, more than three quarters of the colorectal ade-
nomas had at least one chromosomal imbalance and these aberra-
tions included +7, +13q, +20q (14% each) and −18 (6%) [70], all of 
which are also observed in CRCs [14,53– 59]. The aforementioned 
aberrations overlap well with the subclusters in our oncogenetic tree 
models and independently support a model in which +13q, +20q and 
−18q represent early events in tumour development. Of note, so-
matic copy number aberrations affecting chromosomes 3, 7, 9 and 
X have been reported in colorectal epithelium without histological 
evidence of neoplasia [71]. Except for gains at chromosome 7, these 
aberrations do not appear to be enriched in CRCs [14,53– 59], and 
the relevance of these observations remains to be determined.
In this study, we took advantage of an approach that, in addi-
tion to the MMR/MS status, focuses on larger chromosomal copy 
number variations. Along these lines, recurrent, large chromosomal 
aberrations, often at the level of whole chromosomal arms or en-
tire chromosomes, have been established as a major source of copy 
number alterations in CRCs [14,72]: about 80%– 90% of CRCs pres-
ent with whole chromosome or whole chromosomal arm aneuploidy 
[49]. Consistently, we determined in our series that 83% of the CRCs 
showed an apparent copy number change in at least one chromo-
somal arm. Note that genetic variants below the resolution of the 
karyotyping approach and copy number neutral loss of heterozygos-
ity as well as certain structural variants would have been missed, as 
would small- scale mutations.
The pathogenetic significance of aneuploidy is only beginning to 
emerge [23,49,73– 76]. The chromosomal regions that predominantly 
appear to show whole- arm imbalances in CRCs harbour several im-
portant oncogenes and tumour suppressor genes linked to tumour 
development [14,52,58,77]. For example, the long arm of chromo-
some 8 encompasses, amongst others, the oncogene MYC, which 
was found to be overexpressed in CRC [78], and the MYC locus was 
shown to belong to the major sites gained in CRC [52,58] including 
amplifications in a subset of cases [14]. MYC codes for a transcrip-
tion factor favouring cell proliferation [79]. With respect to gains 
and amplifications of 13q, the KLF5 gene encoding a Krüppel- like 
transcription factor involved in the regulation of the cell cycle in ep-
ithelial cells of the intestine [80], has been suggested as candidate 
oncogene for CRC pathogenesis, amongst others [14,52], as was 
HNF4A [14,52] located on chromosome 20q that encodes a tran-
scription factor of the nuclear receptor protein family [81]. Losses 
at −18q have been associated with SMAD4 [77], a member of the 
transforming growth factor beta signaling pathway [82]. However, 
as the expression level of the vast majority of genes appears to be 
linked to the copy number of the respective gene [83,84], additional 
genes in these chromosomal regions may also contribute to cancer 
development.
In conclusion, the present study supports the idea of different 
evolutionary clusters that are dominated by either CIN or dMMR/
MSI- H irrespective of the tumour site and adds evidence to the con-
cept of different genetic pathways being active in CRCs. For CRCs 
marked by CIN as a predominant characteristic, our oncogenetic 
tree models contribute to an evolutionary model of CRCs following 
multiple, interconnected chromosomal aberration pathways. Thus, 
our data support the Vogelgram concept [37], which proposes that 
tumour evolution of CRC is driven by the accumulation of genetic 
alterations in the tumour cells but also suggest a link between the 
timing of individual genetic events and the biological potential of the 
tumour cells.
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